Filing Details
- Accession Number:
- 0001127602-10-011098
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-04-14 13:00:00
- Reporting Period:
- 2010-04-12
- Filing Date:
- 2010-04-14
- Accepted Time:
- 2010-04-14 17:07:21
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1097264 | Allos Therapeutics Inc | ALTH | Pharmaceutical Preparations (2834) | 541655029 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1305811 | H Marc Graboyes | 11080 Circlepoint Road Suite 200 Westminster CO 80020 | Svp, General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2010-04-12 | 75,000 | $2.70 | 132,912 | No | 4 | M | Direct | |
Common Stock | Disposition | 2010-04-12 | 75,000 | $8.58 | 57,912 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Options (Right to Buy) | Disposition | 2010-04-12 | 75,000 | $0.00 | 75,000 | $2.70 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2007-02-10 | 2016-02-10 | No | 4 | M | Direct |
Footnotes
- The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan under which Mr. Graboyes sold a portion of his holdings for tax and estate planning purposes.
- The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $8.53 to $8.60. Upon request of the SEC staff, Allos Therapeutics, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.
- Stock options vest according to the following schedule: One fourth (1/4) of the total number of shares subject to this option shall vest 12 months after the date of grant and an additional one forty-eighths (1/48) of the total number of shares subject to the option shall vest each one month period thereafter, until all such shares are vested and exercisable.